ARGX

argenx NV, based in Breda, the Netherlands, is a leading clinical-stage biotechnology company focused on developing innovative antibody-based therapies for severe autoimmune diseases, hematological disorders, and cancer. Leveraging its proprietary technology platform, argenx is advancing a robust pipeline of therapeutic candidates through multiple clinical trial phases, with the objective of delivering transformative solutions to patients with significant unmet medical needs. As the company continues to capitalize on scientific breakthroughs and expand its portfolio, argenx represents a compelling investment opportunity for institutional investors seeking exposure to the dynamic biopharmaceutical sector.